START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

This study is testing whether adding targeted radiation (stereotactic body radiotherapy, or SBRT) to hormone therapy improves outcomes in men with newly diagnosed prostate cancer that has spread to a small number of sites (called oligometastatic disease). SBRT delivers precise, high-dose radiation directly to tumors. **You may be eligible if...** - You have been diagnosed with prostate cancer that is still responsive to hormone-lowering treatments (castration-sensitive) - You have a limited number of metastatic spots — 3 or fewer on CT/bone scan, or 5 or fewer on a specialized PET scan - Your metastases are in the bones or lymph nodes (not internal organs) - Your bone marrow and organ function are within acceptable ranges **You may NOT be eligible if...** - Your prostate cancer has become resistant to hormone therapy - You have more than 3 or 5 lesions (depending on scan type) - You have metastases in internal organs (visceral disease) - You have previously received certain advanced hormone therapies or docetaxel chemotherapy - You are participating in another clinical trial Talk to your doctor to see if this trial is right for you.